PM
PMVP.US Pmv Pharmaceuticals Inc
- Market cap
- USD 92.2M
- P/E
- -
- P/B
- 1.57x
- ROE
- -164.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PMVP.US undervalued?
Graham numberThe Graham number of Pmv Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pmv Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Pmv Pharmaceuticals Inc yet.
Pmv Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceutical…
Full company profilePmv Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pmv Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -338K | -388K | -318K | -1.28M | -650K | -1.26M | -1.14M | -133K | - |
| Operating Income | -18.9M | -26.6M | -34.9M | -58.3M | -77.0M | -80.1M | -85.4M | -86.2M | -77.3M |
| EBITDA | -18.6M | -25.0M | -34.6M | -58.0M | -76.7M | -67.7M | -73.7M | -79.8M | -75.9M |
| Net Income | -17.5M | -25.4M | -34.4M | -57.8M | -73.3M | -69.0M | -58.7M | -77.7M | -94.0M |
| EPS | -5.80 | -0.59 | -0.77 | -1.28 | -1.61 | -1.44 | -1.14 | -1.48 | -1.42 |
| Balance Sheet | |||||||||
| Total Assets | 63.5M | 103M | 366M | 332M | 270M | 252M | 191M | 117M | 111M |
| Total Liabilities | 110M | 174M | 6.41M | 23.0M | 24.3M | 26.5M | 15.2M | 11.9M | 54.3M |
| Shareholders' Equity | -46.1M | -70.5M | 359M | 309M | 246M | 226M | 176M | 105M | 57.1M |
| Cash & Short-term Investments | 61.9M | 101M | 361M | 297M | 241M | 203M | 169M | 113M | 103M |
| Total Debt | 107M | 169M | - | 11.2M | 14.0M | 13.3M | 1.19M | 838K | 138K |
| Cash Flow | |||||||||
| Operating Cash Flow | -15.2M | -22.1M | -32.7M | -46.6M | -63.8M | -55.7M | -51.3M | -73.6M | -69.9M |
| Capital Expenditure | 452K | 109K | 148K | 1.35M | 7.98M | 962K | 655K | 29.0K | 0.00 |
| Free Cash Flow | -15.6M | -22.2M | -32.9M | -47.9M | -71.7M | -56.6M | -51.9M | -73.6M | -69.9M |
| Ratios | |||||||||
| ROE | - | - | -9.6% | -18.7% | -29.8% | -30.6% | -33.3% | -74.2% | -164.6% |
| ROA | -27.6% | -24.6% | -9.4% | -17.4% | -27.1% | -27.3% | -30.7% | -66.7% | -84.4% |
| Debt to Equity | - | - | - | 0.04x | 0.06x | 0.06x | 0.01x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pmv Pharmaceuticals Inc dividends
Pmv Pharmaceuticals Inc has not paid dividends in the last 8 fiscal years.
Who owns Pmv Pharmaceuticals Inc
- Insiders 2.36%
- Institutions 75.02%
- Public & others 22.62%
- Shares outstanding 75.5M
- Free float 59.2M
Top funds holding PMVP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.38M | 3.16% | +60.35% | Sep 2026 |
| Meridian Small Cap Growth Legacy | 911K | 1.21% | -13.80% | Sep 2026 |
| Bridgeway Ultra-Small Company | 331K | 0.44% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 252K | 0.33% | +17.47% | Sep 2026 |
| iShares Micro-Cap ETF | 146K | 0.19% | 0.00% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 74.8K | 0.10% | 0.00% | Oct 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 74.1K | 0.10% | -4.62% | Jun 2026 |
| Fidelity Total Market Index | 71.2K | 0.09% | 0.00% | Sep 2026 |
| Nationwide Bailard Sm Cp Val M | 61.5K | 0.08% | 0.00% | Jan 2026 |
| Fidelity Series Total Market Index | 59.9K | 0.08% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 45.0K | 0.06% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 41.5K | 0.06% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 27.5K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 21.6K | 0.03% | 0.00% | Sep 2026 |
| NVIT Small Cap Val I | 14.5K | 0.02% | -68.35% | Jun 2026 |
| BlackRock Diversified Equity Alpha Inst | 13.2K | 0.02% | 0.00% | Jul 2026 |
| 1290 VT Micro Cap K | 10.7K | 0.01% | 0.00% | Sep 2026 |
| Avantis Total Equity Markets ETF | 4.72K | 0.01% | 0.00% | Oct 2026 |
Top institutions holding PMVP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BML Capital Management LLC | 7.33M | 9.70% | +37.52% | Sep 2026 |
| TANG CAPITAL MANAGEMENT LLC | 4.25M | 5.62% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 2.63M | 3.49% | -14.38% | Jun 2026 |
| Euclidean Capital LLC | 2.63M | 3.48% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.36M | 3.12% | +26.88% | Jun 2026 |
| Acadian Asset Management LLC | 2.29M | 3.03% | +3.14% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.01M | 2.66% | +1.88% | Jun 2026 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 1.96M | 2.59% | -31.79% | Jun 2026 |
| Two Sigma Investments LLC | 1.95M | 2.59% | +3.69% | Jun 2026 |
| Eversept Partners, LP | 1.89M | 2.50% | -19.48% | Jun 2026 |
| BlackRock Inc | 920K | 1.22% | +5.20% | Jun 2026 |
| Assenagon Asset Management SA | 660K | 0.87% | +82.94% | Jun 2026 |
| Stonepine Capital Management Llc | 536K | 0.71% | -24.29% | Jun 2026 |
| Geode Capital Management, LLC | 473K | 0.63% | -4.59% | Jun 2026 |
| Aldebaran Capital LLC | 467K | 0.62% | -1.25% | Jun 2026 |
| Bridgeway Capital Management, LLC | 429K | 0.57% | 0.00% | Jun 2026 |
| Verdad Advisers, LP | 362K | 0.48% | +101.13% | Jun 2026 |
| Walleye Trading Advisors, LLC | 336K | 0.44% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 322K | 0.43% | -25.91% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 255K | 0.34% | -14.54% | Jun 2026 |
Pmv Pharmaceuticals Inc company profile
- Company name
- Pmv Pharmaceuticals Inc
- Ticker
- PMVP.US
- Exchange
- USA Stocks
- Listed since
- Sep 25, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 54
- Fiscal year end
- December
- Address
- 400 Alexander Park Drive, Princeton, NJ, United States, 08540
- Phone
- 609 642 6670
- Website
- pmvpharma.com
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Pmv Pharmaceuticals Inc management
10- Dr. David H. Mack Ph.D.Co-Founder, CEO, President & Director · born 1962
- Dr. Arnold J. Levine Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory Board · born 1940
- Mr. Robert Ticktin J.D.General Counsel, COO & Company Secretary · born 1962
- Dr. Deepika Jalota Pharm.D.Chief Development Officer · born 1977
- Mr. Michael CarulliCFO & Principal Financial & Accounting Officer · born 1974
- Mr. Tim Smith M.B.A.Senior VP and Head of Corporate Development & Investor Relations
- Mr. Steve DyottVice President of Marketing
- Ms. Crystal ZuckermanVice President of Human Resources
- Dr. Binh Vu Ph.D.Senior Vice President of Drug Discovery & CMC
- Dr. Marc Fellous M.D.Senior VP and Head of Clinical Development & Medical Affairs